The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Open accessAbstract
There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug response phenotype based on genotype, there is very focused and useful phenotypic information to be gained from directly perturbing the patient's living cancer cell with the drug(s) in question. To satisfy this unmet need, we developed the Dynamic BH3 Profiling technique to measure early changes in net pro-apoptotic signaling at the mitochondrion ("priming") induced by chemotherapeutic agents in cancer cells, not requiring prolonged ex vivo culture. We find in cell line and clinical experiments that early drug-induced death signaling measured by Dynamic BH3 Profiling predicts chemotherapy response across many cancer types and many agents, including combinations of chemotherapies. We propose that Dynamic BH3 Profiling can be used as a broadly applicable predictive biomarker to predict cytotoxic response of cancers to chemotherapeutics in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BCL2-homology domain (BH3) profiling 41 demonstrated that cytochrome c release following mitochondrial exposure to pro-apoptotic BH3-only peptides (e.g. BIM BH3, PUMA BH3) was similar in control and Tbk1-null B16 cells (Extended Data Fig. 9a).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [41]
In the citing paper
“Dynamic BH3 profiling robustly predicted which patients would respond to a given therapy across multiple cancer types.”
From Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate (2016) · cites this paper as [29]
In the citing paper
“Montero et al. recently reported a functional approach called ‘dynamic BH3 profiling’, in which therapeutics are applied to cell lines or clinical tumor isolates, and then the percentage of cells that undergo mitochondrial outer membrane permeabilization (MOMP) is measured after introduction of a pro-apoptotic BH3 peptide29.”
From Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate (2016) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
Kluck, R. M., Bossy‐Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,715
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
Joensuu, H., Roberts, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Self-citationSawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,615
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–374 of 374
Unravelling the Role of Biomarker in Cancer Detection: An In-Depth Review
Khamkat, P., Adak, A., Chakraborty, S., Das, B., Das, S., Karati, D., & Mukherjee, S. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00413-2 · Cited by 2
Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells
Çetin, A. E., Topkaya, S. N., Yazıcı, Z. A., & Yalcin-Ozuysal, Ö. (2023) · ACS Sensors · doi:10.1021/acssensors.3c00208 · Cited by 2
Sherekar, S., Todankar, C. S., & Viswanathan, G. A. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00318-0 · Cited by 2
Functional profiling to improve therapy in TCL
Elenitoba‐Johnson, K. S. J. (2019) · Blood · doi:10.1182/blood-2018-12-889741 · Cited by 2
Hagenbourger, F., Bohler, S., & Erlacher, M. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000717 · Cited by 2
Fraser, C. S., Presser, A. G., Sanchorawala, V., Sarosiek, S., & Sarosiek, K. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542159 · Cited by 2
Self-citationCancer Bone Metastasis, Experimental Study
Lu, D.-Y., & Xu, B. (2021) · Acta Scientific Orthopaedics · doi:10.31080/asor.2021.04.0392 · Cited by 2
The Way Ahead: Lessons Learned from Decades of Cancer Research on Thymomas and Thymic Carcinomas
Ströbel, P., & Marx, A. (2024) · Cancers · doi:10.3390/cancers16051040 · Cited by 2
Taha, T. A.-E. A., Omar, S., Abdelsattar, N. K., Mahmoud, M. A.-E., Kamel, M. M., & Hamdy, N. Μ. (2024) · Translational Medicine Communications · doi:10.1186/s41231-024-00181-z · Cited by 1
Regulated cell death programs shaping cancer therapy
Luo, H., & Guo, Y. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01232-3 · Cited by 1
Madiot, C., Bellanger, C., Dousset, C., Decombis, S., Thirouard, L., Papin, A., Baron, E., Barc, J., Bris, Y. L., Gomez‐Bougie, P., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02894-6 · Cited by 1
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies
Sekar, V., Mehrotra, D. G., & Majumder, B. (2016) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-016-0591-4 · Cited by 1
Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
Meszaros, N., LIND, K., Sehlke, R., Vilagos, B., Krall, N., Vladimer, G. I., & Sill, H. (2022) · British Journal of Haematology · doi:10.1111/bjh.18557 · Cited by 1
Great Expectations in Acute Myeloid Leukemia
Khan, M., & Dinardo, C. D. (2016) · Future Oncology · doi:10.2217/fon.15.308
Prediction of individual chemoprophylaxis for radiation carcinogenesis in experiment
Иванов, С. Д. (2017) · Biology Bulletin Reviews · doi:10.1134/s2079086417040041
Fox, J. L. (2017) · Journal of Cell Signaling · doi:10.4172/2576-1471.1000156
Sab Concentration Determines the Chemotherapeutic Efficacy in Gynecological Cancer
Paudel, I. (2018) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc006535
Impact of San-mediated Signaling on Glioblastoma and Neuroblastoma Metabolism
Silva, M. R. (2018) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc006885
Precision Medicine Concepts in T-Cell Lymphoma
Staber, P. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85543
Weigert, O., & Chapuy, B. (2019) · Der Onkologe · doi:10.1007/s00761-019-0644-8
Murakami, M. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Pre-Clinical Assessment of MCL-1 as a Therapeutic Target in T-Cell Lymphomas
Christie, A. L. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Explorando o metabolismo como ferramenta para investigação e tratamento de doenças
Ferreira, V. G. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.75.2020.tde-03072020-092108
Improvisation of Conventional Techniques: The Future of Oncology Research
Rudra, T. (2020) · Asclepius Medical Research and Reviews · doi:10.33309/2639-8605.030104
Merkel Cell Polyomavirus Oncogenes Generate Targetable Synthetic Lethality
Park, D. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Alkylating Agent-Induced ER Stress Overcomes Microenvironmental Resistance to Lymphoma TherapyPreprint
Lossos, C., Kolb, K. E., Christie, A. L., Scoyk, A. V., Prakadan, S. M., Shigamori, K., Stevenson, K. E., Morrow, S. N., Plana, O. D., Fraser, C. S., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3262959
Self-citationImpresionismo de pintores rusos
Angulo, J. S., & Ramos, M. Á. (1997) · Galería Antiqvaria: Arte contemporáneo, antigüedades, mercado, coleccionismo
Dekel‐Bird, N. P., Bialik, S., Itzhaki, O., Salame, T. M., Yaeli-Slonim, N., Levin‐Salomon, V., Dasari, S. K., Besser, M. J., & Kimchi, A. (2022) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079145
(2015) · Nature Biotechnology · doi:10.1038/nbt.3197
Faculty Opinions recommendation of Statins enhance efficacy of venetoclax in blood cancers.
Shah, K. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733450031.793547319
Gilmore, A. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726205394.793566250
Sherekar, S., & Viswanathan, G. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.29.502000
Tu, H., Zhang, Q., Wen, J., Bao, J., & Zhang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1995755/v1
Mitochondria in Cell Death Regulation
Inde, Z., Montero, J., & Sarosiek, K. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00189-9
Self-citationApoptosis signaling in EGFR inhibitor resistance in NSCLC
Aka, Y., Karakaş, B., & Kütük, Ö. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00001-2
Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2023) · doi:10.1158/0008-5472.c.6513486.v1
Self-citationLeto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2023) · doi:10.1158/0008-5472.c.6513486
Self-citationCidado, J. R., Boiko, S., Proia, T. A., Ferguson, D., Criscione, S. W., Martin, M. S., Pop-Damkov, P., Su, N., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2023) · doi:10.1158/1078-0432.22473192
Hemming, M. L., Bhola, P. D., Loycano, M. A., Anderson, J. A., Taddei, M. L., Doyle, L. A., Lavrova, E., Andersen, J. L., Klega, K. S., Benson, M. R., et al. (2023) · doi:10.1158/1078-0432.c.6532647.v1
Self-citationHemming, M. L., Bhola, P. D., Loycano, M. A., Anderson, J. A., Taddei, M. L., Doyle, L. A., Lavrova, E., Andersen, J. L., Klega, K. S., Benson, M. R., et al. (2023) · doi:10.1158/1078-0432.c.6532647
Self-citationChen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., Sakellaropoulos, T., Gong, Y., Kloetgen, A., Yap, Y. S., et al. (2023) · doi:10.1158/2159-8290.22536728.v1
Rosas-Plaza, X., de Vries, G., Meersma, G. J., Suurmeijer, A. J. H., Gietema, J. A., van Vugt, M. A. T. M., & de Jong, S. (2023) · doi:10.1158/1535-7163.22506999
Li, Y., He, X., Zhang, L., Dong, H., Wang, X., Che, Y., Yadav, U. P., Liu, M., Zhang, L., Ge, S., et al. (2024) · Blood · doi:10.1182/blood-2024-203923
Zebrafish xenographs in oncology and personalized medicine
Lunina, N. A., Safina, D. R., & Kostrov, S. V. (2024) · Molecular Biology · doi:10.31857/s0026898424030032
Brakefield, L., Budhraja, A., Hall, P. A., Brewington, D., Moore, J., Lott, J., Ni, Y., Voronin, D., Grant-Chapman, O., Mukiza, T. O., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09037-w
Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020815
Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020809
Zoeller, J. J., Vagodny, A., Daniëls, V. W., Taneja, K., Tan, B. Y., DeRose, Y. S., Fujita, M., Welm, A. L., Letai, A. G., Leverson, J. D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433107
Self-citationZoeller, J. J., Vagodny, A., Daniëls, V. W., Taneja, K., Tan, B. Y., DeRose, Y. S., Fujita, M., Welm, A. L., Letai, A. G., Leverson, J. D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433110
Self-citationProtein S -acylation dynamics provide metabolic plasticity to acute myeloid leukemia cellsPreprint
Balasundaram, N., Erdem, A., Sharda, A., Daniëls, V. W., Chea, P. L., Leguay, F., LIU, Y., Keibler, M. A., Vidoudez, C., Lane, A. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.708949
Shrestha, M., Dahal, S., Shrestha, A., McNally, P., Shrestha, A. B., & Mackler, N. (2026) · eJHaem · doi:10.1002/jha2.70261
TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphomaPreprint
Spoeck, S., Kinz, N., Rigato, I., Hoppe, K., Heppke, J., Petermann, P. Y., Weiss, J. G., Erlacher, M., Schubert, M., Riley, J. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.20.712678
Molecular basis of BCL2L10/Nrh oncogenic activity in breast cancer
Nougarède, A. (2016) · theses.fr (ABES) · doi:10.70675/67283ec1z7040z4d6eza688z407667ae770d
Caractérisation et études précliniques d'un nouvel inhibiteur naturel de MCL-1
Daressy, F. (2020) · theses.fr (ABES) · doi:10.70675/4e4153f4zba2dz49bcz9862z38251f3f7882
Senolytic drug discovery and mechanisms of action in BRAF-V600E oncogene-induced senescence
L’Hôte, V. (2022) · theses.fr (ABES) · doi:10.70675/acd5f426zc1b2z446fz8404z0f8f121081f8
Assessing apoptotic sensitivity by BH3 profiling in primary mouse B cells
Kinz, N., & Riley, J. S. (2026) · Methods in cell biology · doi:10.1016/bs.mcb.2026.05.019
Huang, A. S., Lieschke, E., Baldoni, P. L., Thomas, A., Marchingo, J. M., Whelan, L., Khuu, G., Marca, E. L., Milevskiy, M. J. G., Ross, A. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.01.735749
Bone Tumor Metastasis Therapeutics, New Ideas and Perspectives
Lu, D.-Y., Wu, H., & Che, J.-Y. (2026) · Global Journal of Cancer Therapy · doi:10.17352/2581-5407.000057
Ma, Y., Wu, C., Zhao, Y.-Q., Cui, J., Huang, Y., Fang, W., Yang, Y., Zhao, Y., Yang, C., Pan, W., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014573
Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines
Sveen, A., Stenersen, J. M., Asenso, T. Q., Klokkerud, S. M. K., Kranjec, C., Eilertsen, I. A., Johannessen, B., Leithe, E., Kryeziu, K., Zucknick, M., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00551-z
EXABS-178-AML: Debate: Is Low-Intensity Therapy Appropriate for Younger Patients with AML? (PRO)
Aubrey, B. J., & Fathi, A. T. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00317-4
Abd-Rouf, M. S. K., Adigun, P. O., Faniyi, A. J., Oladapo, B. G., Abd-Rouf, A. B., Alalade, E. O., Awopejo, T. E., Adegoke, O. S., Oyekanmi, T. T., Jamiu, A. B., et al. (2024) · International Journal of Science Research and Technology · doi:10.15662/ijsrat.2024.0703003
Apoptosis in Cancer: From Threat to Therapy
Chagalamari, A., Rangari, G. M., Rao, B., Sharma, S., None, M., Misra, A. K., & Bhaisare, R. G. (2026) · PERSPECTIVES IN MEDICAL RESEARCH · doi:10.47799/pimr.1402.25.84
Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance
Rojas, A., Jethi, S., Budak-Alpdoǧan, T., & Pandey, M. K. (2026) · Genes · doi:10.3390/genes17091122
BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer
Venkatachalam, A., Strathman, A. R., Hou, X., Correia, C., Meng, X. W., McGehee, C. D., Balczewski, E. A., Duffield, L. N., Rossman, O. K., Wong, C., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02870-7
Lin, S., Qin, B., Ye, Z., Qing, J., Zhen, H., Yang, S., Jiang, X., Fan, Y., Zhu, L., & Liu, J. (2026) · Biomolecules · doi:10.3390/biom16091375
SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm
Olesinski, E. A., Aubrey, B. J., & Fathi, A. T. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.016
Live‐cell FRET imaging‐based efficacy prediction of EGFR‐TKIs in EGFR L858R‐mutant NSCLC
Li, X., Dai, L., Yang, P., Li, S., Peng, C., Li, S., Sun, B., Cai, S., Wang, X., & Chen, T. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70878
Markiewicz, H., Murawa, A., Rytelewski, Z., Ślężak, J. K., & Dobosz, P. (2026) · Pharmaceuticals · doi:10.3390/ph19111675
Metadata
- Authors
- Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., Jänne, P. A., Amrein, P. C., Cichowski, K., Drapkin, R., & Letai, A.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Letai, Anthony
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 160
- Issue
- 5
- Pages
- 977-989
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4391197
- OpenAlex
- W2165056381
- Cited by
- 378
- References
- 35
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 19 · 2023: 31 · 2022: 37 · 2021: 36 · 2020: 37 · 2019: 44 · 2018: 40 · 2017: 39 · 2016: 38 · 2015: 16
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U01CA152990, K99CA188679, P01CA139980, P01CA068484, R01CA129974, R01CA135257, R21CA188858, R00CA188679)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- chemotherapy response prediction, predictive biomarkers, apoptosis signaling, drug-induced cell death, combination chemotherapy, cytotoxicity
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Cell Line, Female, Humans, Mitochondria, Neoplasms, Ovarian Neoplasms, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Cell Death, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
